ATRA Atara Biotherapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1604464 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY1,404.0%
TTM net income YoY69.1%
TTM EPS YoY82.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-64.7%
Net margin-66.2%
FCF margin-53.5%
EBITDA margin-61.8%
Returns
ROE-8,768.3%
ROA-62.2%
ROIC (approx.)—
Asset turnover0.94x
Leverage & solvency
Liabilities / assets189.2%
Debt / equity—
Current ratio0.48x
Interest coverage-18.08x
Cash quality & payout
Operating cash flow / net income0.80x
Accruals ratio-12.2%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.22M | $630,000 | $516,000 | $1.59M | $3.45M | $17.57M | $98.15M | $32.75M |
| Cost of revenue | $265,000 | — | — | — | $115,000 | — | — | — |
| Gross profit | $959,000 | — | — | — | $3.34M | — | — | — |
| R&D expense | $1.10M | $1.34M | $164,000 | -$223,000 | $2.92M | $7.31M | $27.43M | $28.72M |
| SG&A expense | $2.83M | $3.81M | $3.60M | $4.28M | $3.99M | $6.51M | $11.47M | $9.44M |
| Operating income | -$2.97M | -$4.72M | -$3.37M | -$2.56M | -$3.57M | $3.20M | $38.80M | -$12.20M |
| Interest expense | — | $191,000 | $830,000 | $894,000 | $909,000 | $972,000 | $1.02M | $1.02M |
| Pretax income | -$2.23M | -$4.83M | -$4.14M | -$3.41M | -$4.28M | $2.39M | $38.01M | -$12.71M |
| Income tax | $0 | $1,000 | $0 | $0 | $28,000 | $3,000 | $0 | -$19,000 |
| Net income | -$2.23M | -$4.83M | -$4.14M | -$3.41M | -$4.30M | $2.39M | $38.01M | -$12.69M |
| EBITDA | -$2.97M | -$4.71M | -$3.34M | -$2.51M | -$3.54M | $3.43M | $40.60M | -$11.10M |
| EPS (basic) | -0.15 | -0.32 | -0.29 | — | -0.32 | 0.20 | 3.53 | — |
| EPS (diluted) | -0.15 | -0.32 | -0.29 | — | -0.32 | 0.19 | 3.50 | — |
| Weighted avg. shares (diluted) | 15.33M | 15.03M | 14.08M | — | 13.56M | 12.31M | 10.85M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $4.05M | $3.22M | $8.36M | $8.48M | $5.74M | $16.90M | $13.99M | $25.18M |
| Short-term investments | $5.86M | $6.65M | — | $0 | $7.97M | $5.42M | $0 | $17.47M |
| Receivables | $691,000 | $318,000 | $0 | $1.25M | $1.91M | $0 | $8.88M | $1.48M |
| Inventory | — | — | — | $0 | $0 | $0 | $0 | $10.65M |
| Current assets | $11.31M | $13.53M | $12.17M | $12.21M | $18.43M | $24.77M | $27.18M | $64.89M |
| PP&E, net | $38,000 | $41,000 | $55,000 | $73,000 | $147,000 | $176,000 | $285,000 | $1.29M |
| Total assets | $18.61M | $21.02M | $20.00M | $20.23M | $30.17M | $36.90M | $62.04M | $109.10M |
| Current liabilities | $6.57M | $6.85M | $5.64M | $14.92M | $18.06M | $14.56M | $47.89M | $134.57M |
| Total liabilities | $56.51M | $58.02M | $57.31M | $58.74M | $66.80M | $71.94M | $117.11M | $206.38M |
| Shareholders' equity | -$37.90M | -$37.00M | -$37.31M | -$38.50M | -$36.63M | -$35.04M | -$55.07M | -$97.28M |
| Shares outstanding | 10.19M | 9.44M | 8.51M | 7.32M | 7.21M | 6.98M | 5.92M | 5.86M |
| Cash flow statement | ||||||||
| Operating cash flow | -$879,000 | -$3.34M | -$3.07M | -$5.70M | -$9.79M | -$7.32M | -$28.14M | -$24.47M |
| Capital expenditure | — | — | — | $0 | $0 | $0 | $0 | $90,000 |
| Free cash flow | — | — | — | -$5.70M | -$9.79M | -$7.32M | -$28.14M | -$24.56M |
| Investing cash flow | $833,000 | -$6.63M | $0 | $8.44M | -$2.42M | -$5.07M | $17.20M | $3.38M |
| Financing cash flow | $880,000 | $4.83M | $2.95M | -$3,000 | $1.05M | $15.30M | -$250,000 | -$328,000 |
| Depreciation & amortization | $3,000 | $14,000 | $29,000 | $49,000 | $36,000 | $236,000 | $1.79M | $1.10M |
| Stock-based compensation | $457,000 | $394,000 | $749,000 | $1.52M | $1.23M | $2.80M | $4.21M | $5.85M |
Free plan shows the latest 8 periods; Pro shows all 53 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.